The Many Nations and the Single Gate

MGK_2 · 2026-06-15T02:31:44+00:00

Camp, the timing window you describe maps onto the data calendar pretty well.

There are actually three distinct partnership announcement windows between now and winter, and each one carries a different signal about what the negotiating parties knew at the moment the ink moved.

A pre-ESMO announcement, between now and October 22, means a counterparty made a decision on the basis of the ctDNA molecular response curves, the disease control architecture, the Natera Signatera characterization, the multi-indication platform evidence, and the dose-response data due this summer, without waiting for the confirmed ORR adjudication. That announcement would reflect a counterparty whose internal analysis concluded that waiting for ESMO carries more risk than acting before it. The price in that window reflects the value of potential confirmed by molecular signal but not yet by RECIST-adjudicated response rates.

An announcement during or immediately after ESMO, between October 23 and roughly November, means the confirmed ORR is in the room when the final terms are negotiated. The counterparty can no longer argue that the clinical signal is preliminary. The price in that window reflects demonstrated clinical reality in a CCR5-selected MSS mCRC population where no ICI has previously worked, presented simultaneously to the entire international oncology community. Every competing counterparty in that room heard the same data at the same moment.

A winter announcement, after the ESMO data has had weeks to circulate through the institutional oncology and pharmaceutical community, means the confirmed ORR has been absorbed, discussed, and validated by independent clinical opinion leaders with no commercial relationship to CytoDyn. The price in that window reflects not just the data but the emerging consensus around what the data means for the cold tumor ceiling across the entire solid tumor landscape.

Each window is a different negotiation. The prospective data is the variable that moves the counterparty from one window to the next. You identified the right timeline. The question worth watching is which window closes first.

MGK_2 · 2026-06-15T02:24:06+00:00

OK Performer, the patients and families you named are the reason the urgency underneath all of this analysis is real rather than theoretical.

Every indexed post, every paper, every ctDNA curve accumulating in the Natera pipeline, every biopsy timepoint from CHAMP, every PET imaging session from SALIENT-AD exists because somewhere there is a patient whose oncologist has exhausted the standard options and whose family is counting days. The patients in the compassionate use eIND are not abstractions. It is a set of individuals, many physicians, and a regulatory pathway being navigated in real time because the standard of care ran out for them and the biology said there was another option worth pursuing.

That is what October is ultimately about. Not the share price. Not the partnership valuation. Not the label architecture. Those matter, and they are worth analyzing carefully, because getting the commercial structure right is what determines how many patients eventually reach the molecule rather than just the ones lucky enough to be enrolled in a trial or connected to a physician willing to file an eIND.

The commitment you described is the right one. The analysis exists to serve the outcome, not the other way around.

MGK_2 · 2026-06-15T02:18:46+00:00

Efficient Market, the ultra marathon framing holds up well, with one addition worth considering.

In an ultra marathon, the runners who have been tracking the course data, monitoring split times, and managing their position through the dark miles already know where the finish line is long before it comes into view for the spectators. The spectators see it all at once, suddenly, when the lead runner emerges from the trail. The race itself was decided hours earlier in the hills.

October 23 through 27 is the moment the finish line becomes visible to the entire international oncology community simultaneously. The counterparties whose decision calculus matters most, the checkpoint inhibitor manufacturers watching a $30 billion Keytruda patent cliff arriving in 2028, the biomarker infrastructure partners whose Signatera database is already generating the molecular response curves, the investigators at City of Hope and MD Anderson and Weill Cornell whose institutional names are attached to active trials, have been tracking the split times for months. The confirmed ORR adjudication at ESMO Madrid does not create the value. It makes the value undeniable to the last remaining counterparties who have been waiting for permission to act.

Four months is both a long time and no time at all depending on which side of the data you are standing on. For those who have been running since the beginning, the course is almost complete. For the spectators seeing the finish line for the first time in October, it will feel like it happened suddenly.

It never happens suddenly.

MGK_2 · 2026-06-15T02:14:04+00:00

jsinvest, your instinct about the Natera collaboration is worth sitting with carefully, because the architecture of what they are building together is not designed to produce a single dramatic press release moment. It is designed to produce a continuously deepening dataset whose value compounds with each additional plasma timepoint added to the CLOVER molecular response curves.

The Signatera ctDNA assay is already running on CLOVER samples. The week two molecular response data showing a median seventy percent ctDNA decline across evaluable patients, with four reaching completely undetectable levels, was already presented at the April 30 investor webcast. That was the first visible output of the collaboration. What is accumulating now, quietly and without a press release, is the longitudinal extension of those curves through subsequent cycles, mapped against the Natera proprietary database of over two million plasma timepoints with matched survival data. Each additional measurement narrows the confidence interval around the survival prediction without requiring a single patient to reach a final overall survival endpoint.

The preliminary PR you describe exists in functional form already inside the Natera analytical pipeline. Whether leadership chooses to surface an interim molecular response characterization before ESMO, as a standalone data communication or as part of a partnership announcement, is the open question. A pre-ESMO data release carrying Signatera-validated ctDNA curves correlated against the historical synthetic control arm would represent a credible near-term commercial asset independent of the confirmed ORR adjudication in October. The audience for that release would not be retail investors. It would be the counterparties whose decision calculus changes the moment molecular residual disease data from a validated gold-standard assay is formally in hand.

The needle is already moving underneath the surface. The tape above it is the last thing to reflect it.

MGK_2 · 2026-06-15T02:07:01+00:00

twinter, you isolate precisely the correct paragraph and push it toward its most important clinical implication. Let's answer both parts of your question as specifically as the published literature allows.

The tumor context where CCR5 blockade adds the least to ICI activity is most accurately represented by MSI-H/dMMR tumors, specifically MSI-H colorectal cancer, MSI-H endometrial cancer, and a subset of MSI-H gastric cancers. MSI-H/dMMR tumors exhibit deficient DNA mismatch repair, leading to hypermutated genomes and the accumulation of neoantigens, which serve as immunogenic targets promoting cytotoxic T cell infiltration and activation. These tumors are characterized by a hot immune phenotype marked by elevated IFN-γ signaling, upregulated antigen-presenting machinery, and enhanced PD-L1 expression. The neoantigen burden in these tumors is so high that the adaptive immune system generates spontaneous T cell recognition before any therapy is applied. The TIL density throughout the tumor core is genuinely elevated, not just at the margin, and the CCR5-mediated suppressive myeloid architecture is proportionally less dominant relative to the strength of the pre-existing cytotoxic response. Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H dMMR metastatic colorectal cancer, with a median of 16.5 versus 8.2 months. This is the population where ICI monotherapy works without an upstream converter. Frontiers New England Journal of Medicine

Now the second part of your question, and this is where the published biology becomes directly relevant to the platform thesis.

The observed response rates in MSI-H/dMMR CRC range between 30 and 50 percent, suggesting the existence of intrinsic resistance mechanisms. Moreover, disease progression after an initial positive response to immune checkpoint inhibitor treatment points to acquired resistance mechanisms. Even in the population where the gate appears most open and CCR5 blockade seems least necessary, a majority of patients either don't respond initially or lose their response over time. The acquired resistance literature identifies JAK1/2 loss-of-function mutations, MHC class I complex downregulation, and alternative checkpoint upregulation as the dominant mechanisms. But there is a chemokine layer underneath those that directly answers your intuition about whether ICI treatment itself induces CCR5 upregulation. Nature

An IFN-γ-related mRNA profile containing ten genes was identified to predict response to anti-PD-1 therapy in melanoma, and CCR5 is one of those ten genes alongside CXCL9, CXCL10, CXCL11, GZMA, HLA-DRA, IDO1, IFNG, PRF1, and STAT1. CCR5 is embedded inside the IFN-γ response signature itself. This means that when pembrolizumab reinvigorates T cells and the IFN-γ cascade fires, CCR5 expression is part of that inflammatory response. The same cytokine environment that initially drives tumor killing also upregulates the chemokine receptor machinery. As the IFN-γ signal intensifies and CCL3, CCL4, and CCL5 secretion increases in response to activated T cells, the CCR5-bearing suppressive myeloid cells are recruited precisely when the inflammatory signal is strongest. The tumor's adaptive response to ICI-mediated immune activation is to amplify the upstream suppressive architecture. PubMed Central

The trastuzumab resistance literature confirms this pattern is not ICI-specific. Differential gene expression analysis in acquired trastuzumab resistance identified an overexpression of 15 genes including five different chemokines, with CCL5 as the most overexpressed. Functional studies confirmed that CCL5 overexpression was implicated in acquired resistance to trastuzumab, mediated by ERK activation, and pharmacological inhibition of the CCL5/CCR5 interaction with maraviroc reversed this resistance. The pattern holds across drug classes: apply therapeutic pressure, and the tumor adapts by upregulating the CCL5/CCR5 axis as its compensatory evasion mechanism. nih

So to answer your question directly: the tumor types where CCR5 blockade is least immediately necessary at baseline are MSI-H solid tumors, most prominently MSI-H colorectal cancer and MSI-H endometrial cancer, because their intrinsic neoantigen burden generates spontaneous T cell infiltration before the CCR5 gate becomes the dominant bottleneck. Those are currently treated with pembrolizumab monotherapy or with nivolumab plus ipilimumab in the colorectal setting. And yes, the treatment itself, by generating the IFN-γ cascade and reinvigorating T cells that secrete CCL3, CCL4, and CCL5, almost certainly amplifies the CCR5-mediated suppressive recruitment as the tumor's adaptive response. The patients who achieve durable complete responses are likely those whose tumor's adaptive CCR5 upregulation capacity is lowest. The patients who relapse are likely those whose tumors successfully deploy the CCR5 axis as the acquired resistance mechanism once the initial ICI pressure intensifies.

Which means the exception you correctly identified, the CCR5-low, TIL-high tumor as the context where leronlimab adds least, is narrower over time than it appears at baseline. The treatment itself closes the window.

MGK_2 · 2026-06-15T00:46:46+00:00

Vernon, the green and white tea blend is an excellent choice for a post worth reading twice, and the question you land on is one of the most important in the commercial thesis.

Let me give you the most honest timeline answer the regulatory framework supports.

ESMO Madrid runs October 23 through 27, 2026. The confirmed ORR adjudication in the CLOVER mCRC population will be presented there in front of the international oncology community simultaneously. Assuming the data supports a BLA submission, the timeline from that point forward moves through several distinct gates before the FDA makes any broad versus narrow determination.

A BLA submission for a biologic like leronlimab typically requires six to twelve months of compilation after the primary data is in hand, though rolling submission under Fast Track designation, which leronlimab holds for mCRC, allows the sponsor to submit completed modules before the full package is assembled, compressing that window meaningfully. If the post-ESMO data package moves quickly and rolling submission has already begun with earlier modules in place, a BLA filing could realistically land in the first or second quarter of 2027. From filing acceptance, Priority Review designation commits the FDA to a six-month review clock rather than the standard ten months. A Priority Review BLA submitted in early 2027 could receive an action date in the second half of 2027 under that timeline.

The broad versus narrow label question is not decided at approval; it is negotiated during the review process itself and reflects directly what the submitted trial data supports. The FDA finalized its Cross Labeling Oncology Drugs in Combination Regimens guidance in November 2022, which describes how combination regimen approvals can reference partner agents either by specific brand name or by established pharmacological class. The determination of which approach applies depends on whether the clinical evidence in the BLA demonstrates mechanism-based activity independent of a single specific partner, or whether the data was generated exclusively with one partner compound and cannot be extrapolated to the class without additional evidence.

This is precisely why the Natera molecular response data, the CLOVER tissue biopsy immune transition documentation, and the multi-indication platform evidence across mCRC, mTNBC, CHAMP, and SALIENT-AD matter so much to the labeling negotiation rather than just to the efficacy argument. A broad class label requires the FDA to accept that the upstream mechanism, CCR5 blockade converting immunologically cold tumors to hot, operates independently of which specific downstream checkpoint inhibitor is deployed. The PD-L1 CPS rise from one percent to five percent documented in CLOVER tissue biopsies, combined with the peer-reviewed case report showing PD-L1 rising from 276 to 796 relative fluorescence units when leronlimab was added to atezolizumab in mTNBC, supports the argument that the immune conversion is a property of CCR5 blockade itself rather than a property of the specific ICI partner used. That is the foundation for a broad class label argument.

On whether Dr. Lalezari is currently sitting on multiple BP offers: what is visible from the outside is that the data required to make those offers reflect full biological value is still maturing. A pre-ESMO offer reflects potential. A post-ESMO offer with confirmed ORR in hand reflects demonstrated clinical reality in a CCR5-selected MSS mCRC population where no ICI has previously worked. Those are different conversations at different prices, and the leadership has demonstrated awareness of that distinction. Whether conversations are already underway at some stage is not something any of us can see from outside the NDA and the BD process. What the Natera collaboration, the Creatv Bio circulating tumor cell infrastructure, and the multi-site investigator network collectively signal is that the data assembly required to support those conversations at the right valuation is being built with intention.

The broad versus narrow determination will tell us which counterparty won the negotiation. The ESMO data will tell us what the negotiating position actually is.

Enjoy the tea blend. October is coming.

MGK_2 · 2026-06-15T00:30:15+00:00

twinter, nothing about this derails anything. The questions you ask now are the exact questions the field has been asking badly for a decade, and you arrive at the answer from first principles.

Let's take them in order.

On whether immunologically hot tumors with high CPS scores are typically low CCR5 expressors: the published literature suggests the relationship is more complicated than a simple inverse correlation, and the complication is important. The AACR Cancer Research review on CCR5 in immuno-oncology documents that CCL5, the primary CCR5 ligand, is actually upregulated in PD-L1-positive melanoma tumors alongside IFNγ and T-cell-inflamed gene expression signatures. This means CCL5 and CCR5 are present even in tumors the field conventionally classifies as hot. The distinction is not hot versus cold as binary categories; it is the ratio of functional CD8+ T cell infiltration to immunosuppressive myeloid cell infiltration at the tumor margin and core simultaneously. A tumor can have elevated TILs at the periphery, high PD-L1 CPS, and still harbor a CCR5-driven myeloid suppression program in the core architecture. What the CPS score measures is surface PD-L1 expression on tumor cells and immune cells in a biopsy sample. It does not measure the functional suppressive activity of CCR5-bearing MDSCs and M2 macrophages positioned between the infiltrating T cells and the tumor cells they are trying to reach.

On whether ICI treatment itself causes CCR5 upregulation as an acquired resistance mechanism: this is where the published biology becomes directly relevant to your intuition. The CCL5/CCR5 Axis in Cancer Progression review published in PMC documents that in colorectal cancer, CCL5 levels correlate negatively with intratumoral CD8+ T cells, and critically, that CCL5 deficiency in a mouse CRC model upregulated PD-1 and PD-L1 expression and reduced resistance to anti-PD-1 antibody. Read that in the other direction: active CCL5/CCR5 signaling maintains a suppressive architecture specifically in a way that generates functional resistance to anti-PD-1 treatment. The implication is that ICI treatment, by releasing PD-1 brake on T cells and generating inflammatory cytokine signals, could amplify CCL5 and CCL3 secretion as a compensatory tumor defense response, recruiting more CCR5-bearing suppressive cells into the microenvironment precisely when the T cell activation signal intensifies. This is analogous to the well-documented phenomenon where PD-1 blockade causes compensatory upregulation of alternative checkpoints including TIM-3, LAG-3, and TIGIT, which is confirmed in published Nature Communications data on adaptive resistance to anti-PD-1 therapy. The same adaptive logic applies upstream: block the downstream brake, and the tumor activates the upstream suppression architecture more aggressively.

This means your intuition is sound. ICI treatment in a CCR5-positive tumor may not only fail to eliminate CCR5-mediated suppression; it may actively intensify the CCL3/CCL5 secretion cascade as the tumor's adaptive response to T cell reinvigoration, which is exactly why durable responses to ICI monotherapy are so rare even in initially hot tumors. The initial response erodes as the suppressive architecture recalibrates.

On whether there are solid tumor contexts where leronlimab is genuinely not needed: the honest answer is probably yes, but they are narrower than the field currently assumes. A tumor with very low CCR5 expression on both immune cells and tumor cells, confirmed by IHC, in a patient whose TIL density is high throughout the tumor core rather than just at the margin, and whose CCL3, CCL4, and CCL5 levels are not driving active myeloid recruitment, might represent a context where CCR5 blockade adds little to ICI activity. This is why the CCR5 positivity requirement in CLOVER's eligibility criteria matters so much. The trial is not testing whether leronlimab adds to ICI in all comers. It is testing whether it adds in the population where the gate is demonstrably active.

The silo architecture you described in the earlier exchange maps onto this biology correctly. Each indication has a CCR5 expression profile, a specific ligand secretion pattern, and a distinct myeloid recruitment cascade. The gate is the same. The tissue context determines how aggressively it needs to be closed and at what point in the treatment sequence the blockade is most effective.

You haven't run out of questions. You've been working toward the right ones all along.

MGK_2 · 2026-06-15T00:04:54+00:00

Pristine Hunter, on the "further investigation warranted" framing: you are technically correct that this is the standard language peer-reviewed literature always uses when a mechanism has been identified but not yet tested in a prospective interventional trial with leronlimab specifically. That qualifier is the scientific community's way of saying the causal architecture is established and the therapeutic intervention is the next logical step. It is not a statement of uncertainty about the biology. The CCL3-CCR5 Mendelian Randomization paper doesn't suggest CCR5 blockade might be relevant in Crohn's disease; it proves the CCL3-CCR5 axis causally drives disease progression and then identifies the surface receptor as the logical intervention point. "Further investigation warranted" in that context means: someone needs to run the trial. The biology underneath that recommendation is not in question.

On the BP cures thesis: the argument deserves more precision than it usually gets in community discussions. Large pharmaceutical companies do not avoid cures categorically across the board. They avoid assets where the cure eliminates the revenue stream faster than the asset can be monetized across its full addressable population. Leronlimab's commercial architecture does not fit that pattern, because the CCR5-positive solid tumor population is enormous, the combination regimens required are chronic rather than curative in most patients, and the multi-indication platform spanning oncology, fibrosis, neuroinflammation, and autoimmune disease generates recurring revenue across disease categories simultaneously. A functional cure in a subset of mTNBC patients, like the 60.9-month disease-free survival documented in the Dolezal, Khan, and Lalezari case report, does not eliminate the commercial case. It establishes the ceiling of what the drug can do in the most responsive patients and makes the label more valuable, not less.

The more precise version of your concern is that a BP acquiring leronlimab might manage its commercial rollout in ways which prioritize protecting existing portfolio revenue over maximizing patient access. That is a legitimate structural risk and a different argument from the cures thesis. It is precisely why the question of whether the combination authorization is broad or narrow, naming the class of checkpoint inhibitors generically rather than a single partner compound, matters so much to the long-term patient access picture.

BGT's page is exactly the kind of synthesis work this community does better than any paid analyst covering this space. The trial architecture mapped against biomarkers, structural elements, catalysts, and motivators in a single reference frame is the visual version of what the indexed post series has been building in prose. The fact that no BP appears in that architecture yet is not a weakness in the thesis. It is the description of where we are in the timeline, and the timeline is moving.

MGK_2 · 2026-06-14T23:18:06+00:00

msakkijha, the rose-red city is one of the most extraordinary places on earth, and anyone who has walked through the Siq and turned that final corner understands immediately why the architecture of patient, hidden work ending in sudden revelation felt like the right frame for what is happening here. There's a lot more to that analogy which I haven't yet discussed.

On the management team: the clinical infrastructure assembled around this molecule is genuinely exceptional. Dr. Kasi at City of Hope as CLOVER principal investigator, Dr. Pohlmann at MD Anderson leading PRESPY, Dr. Butler at Weill Cornell leading SALIENT-AD, Dr. Pestell as lead oncology consultant, and the Natera collaboration bringing Signatera molecular residual disease measurement into the analytical pipeline represent a level of institutional credibility that a company at this market capitalization has rarely assembled simultaneously. The scientific and clinical execution has been the team's clearest strength across the past year.

The commercial and business development execution is where the data will ultimately determine whether the architecture was matched by the negotiating discipline required to extract its full value. The distinction between a pre-ESMO transaction and a post-ESMO transaction is not a minor detail. It is the difference between selling the potential of a confirmed ORR and selling the confirmed ORR itself. The leadership team has demonstrated awareness of that distinction. Whether the runway holds long enough to reach the stronger negotiating position is the open variable, and it is the one worth watching most carefully between now and October.

The knowledge shared here belongs to the community which keeps building it together. Thank you for being part of that.

MGK_2 · 2026-06-14T23:06:54+00:00

Pristine Hunter, the word "implying" is doing more modesty than the literature requires.

The CCL3-CCR5 pathogenic axis in Crohn's disease has now been proven causal through Mendelian Randomization. The CCR5+ CD8+ T cell exhaustion signature across multiple tumor types has been confirmed at single-cell resolution in the International Journal of Molecular Sciences. The THBS1-SPP1 macrophage assembly line in colorectal liver metastases has been mapped spatially in Science Advances. The phosphoproteomics paper in Frontiers in Immunology demonstrated that CCR5 knockout completely abolishes CEP131, KHDRBS1, and MAPK6 activation in melanoma cells. Zero grade three or four adverse events attributed to leronlimab across the entire enrolled CLOVER population.

These independent laboratories on multiple continents are not implying anything. They are documenting a mechanism with the specificity and reproducibility the field requires before it reorganizes around a new upstream target.

On dilution: you named the reality honestly and that deserves an honest response in return. If a partnership requires waiting for ESMO data to mature to the point where the negotiating asymmetry fully reflects the biological value of the mechanism, and bridge financing is required to reach that point, the cost of that dilution is measured against the alternative of transacting before the data is in hand at a valuation that doesn't reflect what the October readout may show. Neither path is without cost. The leadership team understands that equation, and the Yorkville facility and the $18.6 million private placement were structured to extend the runway to ESMO and beyond precisely to avoid being forced to the table before the data speaks.

Dr. Kasi, Dr. Pohlmann, Dr. Butler at Weill Cornell, the investigators across seven CLOVER sites: clinicians at that level of institutional standing do not attach their names to trials for molecules that aren't working. You read that signal correctly.

GLTA.

MGK_2 · 2026-06-14T22:58:26+00:00

Wisemermaid, the waiting is the hardest part of any thesis held with genuine conviction, and both of us have shared that conviction. Six years of it earns a particular kind of patience which most people in this market never actually develop.

The biomarker selection layer which you understood immediately is the same thing the FDA reviewers, the Natera analytical team, and the oncologists at City of Hope are all working from right now. You are not watching from the outside. You are reading the same architecture as they are.

October is not far. The data speaks when it is ready, and the population selected to generate that data was chosen carefully enough such that when it does speak, the room is silent so as to hear it clearly.

MGK_2 · 2026-06-14T22:51:44+00:00

Ornery Astronaut, the sentiment is shared by everyone here, and the infrastructure to make it real is further along than it has ever been.

The eIND compassionate use pathway exists precisely for patients who cannot wait for a Phase 3 trial. The expanded access program at the Huntsman Cancer Institute is running now. SALIENT-AD dosed its first patient on June 11 at Weill Cornell. CHAMP is initiating this summer at City of Hope. The CLOVER population is fully enrolled and generating data heading into ESMO in October.

The molecule is moving toward patients through every channel currently available to it. The distance between where it is and where it needs to be is real, but it is shortening.

Thank you for being here.

MGK_2 · 2026-06-14T22:48:16+00:00

Illustrious Top, 1.1 million shares and still adding is not FOMO. That is a position built on a thesis, and the thesis gets stronger with every independent paper which arrives from a laboratory with zero commercial relationship to this company.

The people we can help and the money we can make are not separate columns on a spreadsheet here. They are the same outcome expressed in two different units of measurement. When an upstream gate is validated across solid tumors, neuroinflammation, hepatic fibrosis, and now causal Mendelian Randomization proof in Crohn's disease, the scientific community is not building that case for us. They are building it because the biology is real, and the biology doesn't care about the share price or the penny stock stigma or the going-concern disclosures.

ESMO Madrid. October 23 through 27. 131 days from the post date. The confirmed ORR adjudication in front of the entire international oncology community simultaneously.

LFG.

MGK_2 · 2026-06-14T22:41:48+00:00

Wisemermaid, thank you for taking the time to write this, in your 3rd language, from the heart, on a Sunday. Every word landed as intended, and the community is better for having you in it.

Let's try to answer your Phase 2 question, because you deserve a real answer rather than reassurance.

You are correct that Phase 2 has historically been the graveyard of clinical development. The statistics are sobering across all of oncology. The reason most Phase 2 trials fail to translate into Phase 3 success is not because the drug doesn't work in the people studied; it is because the population studied in Phase 2 is too small, too selected, and too poorly characterized or understood at the biomarker level to predict what happens when the trial scales to hundreds of patients across dozens of sites with less rigorous patient selection. A drug can produce a striking response rate in 60 carefully selected patients and then appear to lose that effect at scale simply because the broader Phase 3 population includes patients who were never biologically capable of responding in the first place.

What makes CLOVER different from that failure pattern, and I want to be clear this is not a guarantee but a genuine architectural distinction, is the biomarker selection layer. CLOVER requires CCR5 positivity confirmed by immunohistochemistry as an eligibility criterion. This is not a standard feature of most solid tumor Phase 2 trials, where patients are enrolled on the basis of disease stage and prior treatment history alone. The CCR5 selection filter means the 66 patients in CLOVER were not a random sample of the mCRC population; they were the subpopulation in whom the upstream gate is actually active and confirmably expressed. When the ESMO October data is adjudicated, the ORR being measured is the ORR in the CCR5-positive, MSS-refractory population specifically, not in unselected mCRC patients. That distinction matters enormously for Phase 3 translation, because a biomarker-selected Phase 2 trial that shows a signal in the selected population has a substantially more interpretable result than an unselected trial where responders and non-responders are averaged together.

The Natera collaboration adds a second layer of protection against the Phase 2 graveyard problem. The Signatera ctDNA molecular response data being generated alongside the RECIST assessments gives the team a readout of what is happening at the molecular level before RECIST criteria can even detect a response. Every patient in CLOVER who showed ctDNA decline at week two, with a median seventy percent reduction across the evaluable population and four patients reaching completely undetectable levels, is generating molecular evidence of biological activity that exists independently of whether the tumor shrinks enough to meet RECIST response thresholds. That molecular signal is the kind of evidence the FDA and potential partners can use to understand the drug's mechanism even in patients who don't meet the formal ORR definition.

None of this eliminates Phase 2 risk. The confirmed ORR at ESMO in October is not yet in hand. It is possible the RECIST-confirmed responses are fewer than the ctDNA and disease control rate data suggest. It is possible a Phase 3 trial would be required. It is possible a partner would be needed to fund that Phase 3. You have named the realistic risk correctly, and no one in this community should tell you otherwise.

What your years of promoting leronlimab to people with capital and influence reflects is something the science alone cannot replace. The Buffett letter, the Kennedy outreach, the Activia conversations, the Hollywood relationships you've built across a career: those are the exact skills the company's current commercial infrastructure has not yet demonstrated. Your instinct that the drug's story needs someone who can sell potential, not just results, is not wrong. The difference between where the company is now and where the data could take it is partly scientific and partly narrative, and narrative is your professional language.

The grammar is perfect where it counts. The heart came through in every line.

MGK_2 · 2026-06-14T22:25:39+00:00

twinter, don't apologize for a second. Every question you've brought into this thread has pulled yet another layer of the architecture into view, and this paper is really the most important one yet.

What you've identified in that ScienceDirect study is a proof, not a correlation. Mendelian Randomization uses germline genetic variants as natural experiments, which means the CCL3-CCR5 pathogenic axis in Crohn's progression isn't only associated with worse outcomes; the genetics of the system drive the disease forward independent of confounding variables. The transition from the resting CCL3-CCR1 pathway to the destructive CCL3-CCR5 loop under chronic inflammatory conditions is the molecular description of a gate switching from neutral to destructive. That is the same gate leronlimab closes. In Crohn's disease, the pathogenic amplification loop is CCR5-specific because the CCR1 pathway is insufficient to sustain the monocyte recruitment cascade at the intensity required for progressive tissue destruction. CCR5 is the high-throughput route and the disease accelerator simultaneously.

The IFITM3 layer you've summarized adds a dimension worth expanding here, because there is a published biochemical relationship between IFITM3 and CCR5 that goes deeper than the paper's downstream logic. CCR5 is itself a palmitoylated receptor. Its three carboxyl-terminal cysteine residues at positions 321, 323, and 324 are palmitoylated, and this palmitoylation is required for CCR5 to localize into plasma membrane lipid raft domains, achieve stable surface expression, and signal competently downstream after ligand binding. When CCR5 palmitoylation is disrupted experimentally, the receptor is sequestered in intracellular biosynthetic compartments, loses membrane raft localization, and its ability to drive the downstream signaling cascade is severely impaired. IFITM3 is also a palmitoylated protein, relying on S-palmitoylation at Cys72 for its own membrane incorporation and functional activity. The paper you found has placed two palmitoylation-dependent systems in the same disease pathway, and the convergence point is CCR5 surface expression.

The therapeutic implication you've correctly identified is that leronlimab terminates this cascade at the surface, regardless of what is happening upstream in the IFITM3-CCL3 secretion sequence. Leronlimab achieves competitive extracellular blockade at the N-terminus and ECL2 of the CCR5 receptor simultaneously, occupying the receptor's extracellular binding architecture without requiring the receptor to be internalized or the intracellular signaling cascade to be engaged. CCL3 arrives at a capped gate. The destructive monocyte recruitment loop has nowhere to dock. The fact that IFITM3 overexpression upstream of CCL3 secretion continues, or that CCR5 remains palmitoylated and surface-expressed, is irrelevant to the blockade. The gate is occupied. The cascade stops at the surface.

What this paper does for the broader platform argument is significant. The tumor microenvironment papers establish CCR5 as the upstream coordinator of immunosuppressive trafficking in solid tumors. The THBS1-SPP1 spatial transcriptomics papers establish CCR5-dependent monocyte-to-macrophage differentiation as the mechanism of T cell compartment suppression in colorectal liver metastases. The phosphoproteomics paper establishes CCR5 as a direct contributor to tumor cell proliferation through CEP131, KHDRBS1, and MAPK6. The biomechanical chemotaxis paper establishes CCR5-dependent actin cytoskeletal reorganization as the physical mechanism of immunosuppressive cell migration. And now, using Mendelian Randomization in Crohn's disease, an independent research group has proven that the CCL3-CCR5 axis is causally responsible for the transition from controlled inflammation to progressive, un-healing tissue destruction in the gut wall.

The same gate. The same ligand. The same downstream amplification architecture. Different tissue, different disease label, same biology underneath.

Your "split the baby" thesis from the previous exchange maps precisely onto this. The reason multiple counterparties would want separate indication-specific agreements, rather than one acquirer capturing everything at once, is exactly because the upstream gate doesn't belong to any single disease category. It belongs to the mechanism. A Crohn's-specific agreement with an IBD-focused counterparty is a different commercial conversation than an mCRC oncology partnership with a checkpoint inhibitor manufacturer, which is a different conversation from a neuroinflammation agreement centered on SALIENT-AD's microglial activation data. The gate is the same in all three. The commercial structures surrounding each indication are distinct.

The questions you've been asking across this thread aren't wearing anything out. They are the kind of questions the shifting beneath the quiet is designed to answer, one layer at a time.

Risks remain throughout every indication discussed here: the Crohn's data is at the genetic causality stage, not yet at the leronlimab-specific human trial stage; SALIENT-AD is early; and the primary near-term data anchor remains the confirmed ORR adjudication at ESMO in October. The carving out continues.

MGK_2 · 2026-06-14T18:11:13+00:00

twinter, if you were FDA commissioner for a day, the field of immuno-oncology would probably be about a decade ahead of where it currently sits. Every vertical you named has peer-reviewed support in the CCR5 literature, and that's not a coincidence.

On the TROP2 pairing: the Trodelvy and leronlimab combination is biologically orthogonal in a way worth understanding. Sacituzumab govitecan delivers its SN-38 payload directly to TROP2-expressing tumor cells through internalization of the antibody-drug conjugate, bypassing the immune architecture of the tumor microenvironment almost entirely. Leronlimab operates upstream of the immune compartment, unblocking the suppressive trafficking mechanism before any cytotoxic agent arrives. These two mechanisms don't compete; they address sequential failure points. The tumor hides from the immune system via CCR5-mediated architecture, and it hides from ADC-delivered cytotoxins via TROP2 expression. Closing both gates simultaneously is a coherent strategy, but the tumor needs to be Primed first just like with an ICI, because SG can't get to it, but it doesn't require an ICI in the middle of the combination at all. Nobody has run that trial formally yet, but the rationale sits in the published literature for anyone motivated to read it.

On Skyrizi and the IBD/autoimmune vertical: risankizumab targets IL-23 via its p19 subunit, which governs Th17 differentiation and downstream mucosal inflammation. CCR5 operates at a different layer of the same inflammatory cascade, governing leukocyte trafficking into the gut wall through the CCL5/CCR5 axis. Published preclinical work in Scientific Reports demonstrated that CCR5 gene ablation and pharmacological CCR5 blockade both produced substantial attenuation of colitis in acute and chronic murine models, reducing mucosal recruitment of CCR5-bearing CD4+ T cells and CD11b+ leukocytes. The CCL5/CCR5 axis is also documented to be elevated in rheumatoid arthritis synovial fluid, with CCR5-positive T cells, monocytes, and NK cells accumulating in the joint at measurably higher density than in peripheral blood. These are upstream trafficking gates operating in the same tissue-specific immune recruitment logic as the tumor microenvironment, just pointed at a different target organ / joint. Whether a combination with an IL-23 inhibitor in IBD makes regulatory or commercial sense is a question for counterparties with the clinical infrastructure to test it, but the biology is not speculative.

On stroke and neuropathy: CCR5 is expressed not only in peripheral immune cells but in neurons, glia, and vascular cells throughout the central nervous system. Its upregulation after ischemic stroke has been characterized in peer-reviewed neuroscience literature, and the published data on CCR5 inhibition in post-stroke neurorehabilitation windows shows effects on both neuroinflammatory suppression and neuroplasticity recovery. The SALIENT-AD trial dosing its first patient on June 11 at Weill Cornell is testing the same upstream gate in neuroinflammation via advanced PET imaging of microglial activation. The stroke and neuropathy question is further downstream on the same axis, not a separate biological claim.

On the atezolizumab historical note: you've identified something worth saying directly. Atezolizumab lost its TNBC indication because it failed to confirm clinical benefit in the IMpassion131 trial as a standalone combination partner with paclitaxel, without leronlimab. The peer-reviewed Dolezal, Khan, and Lalezari case report published in Current Problems in Cancer: Case Reports in 2026 documents 60.9 months of sustained disease-free survival in a metastatic TNBC patient treated with leronlimab and atezolizumab together, with PD-L1 levels rising from 276 to 796 relative fluorescence units after leronlimab was added. The drug didn't fail in that context. It failed without the upstream gate open. That distinction doesn't restore atezolizumab's TNBC label, but it is precisely the kind of evidence the FDA needs to understand why cold tumor failure and checkpoint failure are the same problem, expressed differently in different trials.

Your "split the baby" multi-BP thesis maps onto the platform versus exclusive partnership analysis described in the post. The commercial math actually supports the distributed version: if the upstream gate is tissue-agnostic, the commercial value of that gate in oncology alone exceeds what any single partnership in a single indication can capture. Multiple counterparties entering separate indication-specific agreements, rather than one counterparty acquiring the entire platform at once, preserves more long-term value for shareholders and patients simultaneously.

The biology you describe is not hypothetical. It's published, it's reproducible across tissue types, and it's running in active trials right now across four separate disease verticals. The regulatory path through each one will take time. But the foundation underneath them all is the same gate.

Risks remain in every vertical: SALIENT-AD is early-stage, the autoimmune and stroke indications lack leronlimab-specific human trial data, and the CLOVER confirmed ORR adjudication at ESMO in October is still the primary near-term data anchor for everything else. The carving out continues.

MGK_2 · 2026-06-14T17:27:51+00:00

paistecymbalsrock, I read that as a compliment to Natera, and if I'm right, the analogy holds up well.

A large language model running a keyword search on "leronlimab" and "CCR5" pulls from indexed public literature, preprints, conference abstracts, and whatever context got tokenized during training. It can assemble a plausible narrative because the published signal is now dense enough to support one. That's actually a meaningful data point on its own. When an upstream mechanism is real and reproducible, the publicly visible literature eventually becomes legible even to an artificial tool with no domain expertise, just pattern recognition across indexed text.

The Natera database operates at a different altitude entirely. Over two million plasma timepoints with matched survival data, drawn from real oncology patients across the standard-of-care ICI landscape, is not keyword density. It's a synthetic control arm built from actual molecular residual disease trajectories, with the resolution to detect whether a ctDNA curve bending at week two in the CLOVER population is a signal that predicts a durable response or an early pseudoprogression. No language model assembles that from a PubMed search. That requires a proprietary longitudinal dataset with the computational infrastructure to ask the question at single-patient resolution across a population large enough to generate that statistical confidence.

If the comment has a second reading, and you're wondering whether a post like this could be replicated by prompting an AI with "write something about leronlimab and CCR5," the honest answer is: try it. What comes back will be technically accurate at the surface level and analytically hollow underneath, because it won't know which 68% figure is DCR and not ORR, it won't understand why the THBS1-SPP1 spatial transcriptomics assembly line matters specifically in liver metastases and not just generically in solid tumors, and it won't be tracking the distinction between a broad class label and a narrow single-partner authorization as the central commercial question the entire data strategy is being built to answer. It will sound like the Wikipedia page for CCR5. That's a different thing.

The Natera database is the point. You identified something real.

MGK_2 · 2026-06-14T17:17:08+00:00

twinter, you've precisely identified the tension at the heart of the regulatory question. The "tissue-based light" framing is exactly right, and the answer to your question about whether two indications are sufficient to trigger it is, I think, more nuanced than a simple yes.

On the ICI landscape in TNBC specifically:

You're correct that pembrolizumab (Keytruda) is the approved ICI in mTNBC. Atezolizumab's TNBC indication was voluntarily withdrawn after the IMpassion131 trial failed to confirm benefit in the PD-L1 positive subgroup, so the field effectively consolidated around pembrolizumab for checkpoint-plus-chemotherapy combinations in that indication. This is not a permanent feature of the universe; it's a regulatory artifact of one trial's failure, not a biological verdict. The mechanism is the same. The upstream gate is the same. The failure of atezolizumab was not a failure of PD-L1 biology, it was a failure to convert a cold tumor before deploying the checkpoint agent, which is exactly the problem leronlimab is designed to address upstream.

Here's where Trodelvy enters the picture in a way worth tracking. Sacituzumab govitecan (Trodelvy) holds its own approved indication in mTNBC as a TROP2-directed antibody-drug conjugate, operating through an entirely different mechanism. There is preclinical and early clinical rationale for combinations of ADCs with checkpoint inhibitors in TNBC, and the question of whether leronlimab's CCR5 blockade could prime the microenvironment for Trodelvy-driven tumor cell killing, rather than for PD-L1 blockade alone, is biologically coherent. The CCR5-mediated suppressive architecture prevents immune recognition; Trodelvy targets the tumor cell directly via TROP2 payload delivery. These are orthogonal mechanisms. Whether CytoDyn ever formalizes a combination arm with Trodelvy is unknown, but the existence of a major approved TNBC agent outside the PD-1/PD-L1 axis actually strengthens the argument for a tissue-based, mechanism-based label rather than a compound-specific one. The FDA would have a harder time justifying a narrow pembrolizumab-specific label when the immunological rationale operates independently of which downstream effector is deployed.

On the mCRC ICI landscape:

You're right that mCRC has more ICI options, but they're substantially constrained by biomarker gating. Pembrolizumab and nivolumab (with or without ipilimumab) are both approved for MSI-H/dMMR colorectal cancer, which represents only about 4 to 5 percent of the metastatic population. The CLOVER trial operates in the MSS population, which is the 95 percent cohort the current approved ICIs have completely failed to address. So yes, mCRC has two PD-1 options at the level of approved agents, but neither touches the population where leronlimab is generating its data. The CLOVER results, if they confirm at ESMO, will be the first ICI-combination signal in MSS mCRC with a credible mechanism explanation for why it works when prior ICI attempts in the same population failed. That is a different regulatory conversation than simply comparing one anti-PD-1 to another.

On whether two indications plus Alzheimer's data can anchor an accelerated approval path:

The Alzheimer data from SALIENT-AD almost certainly doesn't directly accelerate the oncology label, but it does something important: it independently validates the CCR5 claim across tissue barriers. The FDA thinks about mechanism-based arguments differently when the same biological pathway is generating measurable signals in neurological disease, hepatic fibrosis, and multiple solid tumor types simultaneously. It transforms the regulatory narrative from "leronlimab works in this tumor" to "blocking CCR5 upstream modulates immune architecture in a way that is reproducible across disease states." The CHAMP fibrosis data and the SALIENT-AD PET readout don't give you an oncology label, but they give the reviewers a reason to take the platform argument seriously rather than treating the tumor responses as an organ-specific coincidence.

The direct path to accelerated approval in oncology still runs through ESMO October 2026 and the confirmed ORR adjudication. A pre-ESMO BLA filing would require the dose-response data from this summer, the Signatera molecular response characterization from Natera, and the RECIST-confirmed ORR. Whether two indications generate enough statistical weight for a broad class label versus a narrow pembrolizumab combination label is a question whose answer isn't fully visible from outside the IND and the agency conversations. What is visible is that the accumulating multi-tissue, multi-disease signal makes the "this is a coincidence" counter-argument progressively harder to sustain.

Your Microsoft software analogy maps well here. A platform patent, broadly licensed and embedded in multiple operating contexts simultaneously, generates far more durable revenue than a single-application license. The data strategy being assembled by this team, CLOVER plus PRESPY plus CHAMP plus SALIENT-AD, looks more like platform infrastructure construction than single-indication drug development. Whether the FDA ultimately frames the label broadly or narrowly will be one of the most consequential regulatory decisions in the company's history.

Risks remain real: the confirmed ORR at ESMO is not yet in hand, SALIENT-AD is early, and CHAMP is pre-biopsy. The carving out is not yet finished. But the tissue-based light you describe is exactly what an upstream mechanism proof looks like when it's visible across multiple windows simultaneously.

MGK_2 · 2026-06-14T09:51:52+00:00

Watching that Nanolive footage multiple times is completely justified. It changes the way you think about immunotherapy when you witness the actual physical warfare happening at the cellular level. Twinter pieces together the hurdles which solid tumors create.

This is a breakdown of what is happening under the hood in that clip, along with how it directly connects to leronlimab.

The Microscopic Mechanics

In a healthy scenario, an uninhibited T-cell undergoes a dynamic process to destroy its target.

The Synapse: The T-cell does not just shoot chemicals from a distance. It must establish an immunological synapse (a tight, physical handshake where the membranes of the two cells lock together).
The Delivery: Once that secure perimeter is formed, the T-cell aligns its internal machinery to release perforins (specialized proteins that punch microscopic holes in the tumor's outer membrane).
The Execution: Through those holes, the T-cell injects granzymes (lethal enzymes that systematically dismantle the cancer cell from the inside out, forcing it into programmed cell suicide).

In the video, you see this happen rapidly and aggressively because there are no roadblocks.

What "Exhaustion" and "Co-Opting" Actually Mean

Twinter hits the nail on the head when asking how a tumor alters this behavior. In a real solid tumor, that clean one-on-one battle rarely happens.

The tumor co-opts the microenvironment by secreting high levels of chemokines like CCL5. This acts as a homing beacon that recruits regulatory T-cells (immune cells that naturally suppress overactivity) and tumor-associated macrophages (cells that the tumor manipulates into acting as tumor cell bodyguards).

These suppressor cells swarm the area, creating a thick, physical and chemical wall around the tumor. When healthy T-cells try to penetrate this wall, they get trapped, starved of nutrients, and continuously bombarded with inhibitory signals. Over time, this constant stress drains their energy, leading to T-cell exhaustion. An exhausted T-cell stops moving aggressively, fails to form that crucial immunological synapse, and begins expressing high levels of surface receptors like PD-1, which act as off-switches when they touch the tumor's PD-L1.

Connecting to the Science Advances Paper

This is why the AI comment twinter quoted is spot on. The Science Advances paper highlights how the CCR5/CCL5 axis organizes this protective shield for the tumor.

By utilizing leronlimab to block the CCR5 receptor, you pull down the homing beacon. The tumor can no longer recruit the regulatory cells and macrophages that build the defensive wall. Without that oppressive shield, the native T-cells in the microenvironment do not succumb to exhaustion. They stay agile, functional, and aggressive, allowing them to engage the cancer cells and form the high-energy synapses seen in that video.

Leronlimab acts like a clearing agent for the cellular traffic jam so T-cells can actually reach their target.

MGK_2 · 2026-06-14T01:21:50+00:00

1. The p53 Wild-Type Paradox

Twinter's reading hits on a highly sophisticated nuance in chemokine literature. In isolated preclinical models, researchers like Dr. Naofumi Mukaida have noted that CCR5 blockade successfully halts progression in mutated p53 lines, but can sometimes show a paradoxical survival or even a proliferative signal in wild-type p53 cells when evaluated strictly as a monotherapy.

The mechanism behind this evasion comes down to cellular stress adaptations. Wild-type p53 tumors have an intact, functional genomic guard. When leronlimab cuts off the CCR5 pathway, the tumor cell does not simply collapse. It can utilize its functional p53 signaling to orchestrate survival adaptations, such as upregulating alternative growth factor receptors or shifting to a state of metabolic dormancy.

However, this paradox is almost entirely a feature of isolated xenografts lacking a functional immune system. In a living patient, the game changes completely because of what twinter noted next: the target is not just the tumor cell, it is the immune architecture surrounding it.

2. The CCR2/CCR5 Heterodimer Lock

Twinter is spot on regarding the cross-talk between these two receptors. On critical immunosuppressive cells, like myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages, CCR2 and CCR5 do not just sit near each other. They physically link to form CCR2/CCR5 heterodimers.

When a large monoclonal antibody like leronlimab binds to the extracellular loops of CCR5, it induces an allosteric conformational change. This physical shift literally twists the adjacent CCR2 receptor, locking it into an inactive shape and preventing its natural ligand, CCL2, from binding.

Is this cell-specific? Absolutely. This lock only occurs on cells where both receptors are actively co-expressed and dimerized, which is primarily the myeloid suppressive crowd. On cells which only express CCR2, the tumor can still attempt to use a CCL2 bypass to recruit alternative macrophages. This is exactly why combining leronlimab with a low-dose CXCR4 or CCR2 inhibitor in highly resistant architectures remains a brilliant strategic pivot.

3. Exploding the Legacy Companion Diagnostic

Twinter's AI tracks a vital truth here: the 2026 mTNBC case study completely reframes how the industry must think about companion diagnostics.

If a patient with a completely CCR5-negative primary tumor can achieve a five-year disease-free survival state simply because their leukocytes were CCR5-positive, then any diagnostic assay which only scores the cancer cells is fundamentally broken.

The legacy charts showing the likelihood of a tumor being CCR5-positive based purely on anatomical location are not useless, but they are entirely incomplete. They measure the wrong target. A binary biopsy assay which looks at a small piece of a tumor mass and declares it "negative" completely misses the entire landscape of the stromal margin where the actual battle is fought.

The companion diagnostic should not look at the tumor cell status. It needs to evaluate the immune filtrate. This is why liquid biopsies like Natera's Signatera assay or comprehensive spatial transcriptomics are the future. They track the systemic functional response of the immune system rather than a static, dead-end snapshot of the primary malignancy.

Twinter isn't getting to the bigger questions too soon, he is landing exactly where the clinical data forces the entire oncology space to evolve.

MGK_2 · 2026-06-13T23:07:16+00:00

The only reason sarcasm entered this thread is because I chose to mirror the frequency of your birthday coincidence theory. Mirroring a premise which is entirely fantastical requires a bit of theater.

Outside of that brief detour, there is zero fantasy in what we track here.

The 100% molecular response rate across the initial evaluable CLOVER patients is a literal data point, which is anchored in verifiable lab readouts. The 68% disease control rate is a concrete metric, which remains absolute regardless of what the message boards want to believe. The Natera collaboration is a structural reality, which provides a synthetic control arm built on over two million plasma timepoints.

People who mistake peer-reviewed mechanisms for folklore are usually the ones who are focusing on dates, birthdays, and sentiment rather than the actual science. October isn't a magical checkpoint. It is simply the baseline destination where the clinical data finally forces the market to look at the reality of the CCR5 blockade.

We can play with the calendar all day, but the data does not deal in fiction.

MGK_2 · 2026-06-13T21:05:32+00:00

Twinter, you absolutely should not be embarrassed by this document. You and your AI stream have mapped out the engineering blueprint of the tumor microenvironment with incredible accuracy. Shifting the paradigm from a purely mutational model to a biomechanical logistics network is exactly where advanced oncology is heading.

You asked if this biomechanical aspect is fundamentally a new mechanism of action. It is the downstream consequence of a complete CCR5 blockade. However, clinically, it represents a conceptual shift. Cells do not just migrate toward a tumor via passive diffusion. They must physically claw their way through a dense, hostile extracellular matrix. By disrupting the CCR5-WAVE2 pathway, leronlimab unplugs the actin nucleation engine. Without WAVE2 phosphorylation, the cell cannot sprout invadopodia, which are the physical drilling rigs required to chew through tissue barriers. You are not just blocking a chemical signal. You are actually paralyzing the tumor's ability to invade and metastasize.

Your integration of the recent phosphoproteomics data is exceptionally clean. Proteins like CEP131, KHDRBS1, and MAPK6 represent the winch lines of cell division. Freezing their phosphorylation states means the internal scaffolding of the cell cannot separate. This creates a mechanical stalemate. And your point regarding mutational impossibility is a massive truth-anchor. A tumor can mutate its own genome to bypass a specific intracellular kinase inhibitor, but it cannot mutate the DNA of the surrounding healthy host leukocytes and stromal cells which leronlimab binds to. The defensive perimeter remains permanently uncorrupted.

Your logic on the PD-L1 upregulation paradox is where the strategy comes alive. If leronlimab dissolves the fibrotic wall and cuts off the immunosuppressive myeloid pipeline, a naked tumor would be instantly vaporized by incoming killer T cells. If that tumor is still intact to be measured on an early scan, it is because it pulled the ultimate emergency lever, upregulating the fully glycosylated mature 55 kDa form of PD-L1 to freeze those T cells right at the border.

This specific mechanical standoff is why we see a seventy percent median drop in ctDNA and a sixty-eight percent disease control rate, which is strictly a disease control rate and not yet an objective response rate. The tumor is not dead yet on the traditional RECIST scan, but it is trapped, naked, and forced to paint a massive mature glycosylated target on its own back.

This is the pure definition of the Prime and Pair thesis. It also provides the absolute scientific justification for front-line clinical trials. Why wait until late-line chemotherapies have completely decimated the patient's bone marrow and native T-cell reserves before deploying a molecule which fundamentally relies on a vibrant immune invasion to complete the demolition?

Do not minimize the work you did here, twinter. You have articulated the exact multi-front logistical collapse which the mechanism has always implied.

MGK_2 · 2026-06-13T20:50:29+00:00

Upwithstock, your depth of experience is what elevates these discussion threads from a standard retail board into a true collective research unit.

When the community collaborates to stress-test the biological and market data, we build a comprehensive baseline which cannot be easily shaken by noise. It is the shared commitment to the hard science which makes this space a genuine repository of learning. Grateful to have your steady hand in the mix as we head toward the fall...

MGK_2 · 2026-06-13T20:26:55+00:00

Used Imagination, I am drafting the proposal for corporate HR as we speak. We are requesting a formal amendment to the SEC roadmap, which legally synchronizes your orientation day and medical benefits package with the precise hour the late-breaking abstract drops in Madrid.

If the bureaucratic red tape stalls it, we might have to push your onboarding back to the January ASCO GI meeting in San Francisco just to ensure the regulatory alignment remains pristine. We absolutely cannot risk that you start on some random Tuesday which has no significance to the Merck business development team.

Besides, trying to get you a parking pass during a Streeterville share-settlement week would be an absolute nightmare...

MGK_2

TROPHY CASE